Gastroprotective agents in mucosal defense against Helicobacter pylori.
1. Convincing evidence now exists that infection with H. pylori plays a major role in the pathogenesis of gastric disease. Having a niche bordering two major perimeters of mucosal defenses, the bacterium apparently exerts its detrimental effect on the mucus layer as well as the gastric epithelium. Therefore, gastroprotective agents capable of counteracting these detrimental effects of H. pylori are gaining importance in the treatment of gastric disease. 2. The colonization of gastric mucosa by H. pylori involves specific glycolipid receptors bearing acidic substituents, a process inhibited by gastric sulfomucins. Two antiulcer agents bearing sulfated sugar groups have been demonstrated to possess the ability to interfere with H. pylori colonization process. These are sucralfate and sulglycotide. The two agents are also potent inhibitors of H. pylori glycosulfatase activity directed against indigenous mucosal defenses. 3. A variety of extracellular enzymes such as proteases, lipases and phospholipases, elaborated by H. pylori cause the weakening of the integrity of gastric mucus coat and render the underlying epithelium vulnerable to noxious luminal contents. Among the most potent agents capable of countering the proteolytic activity of H. pylori are nitecapone, ebrotidine and sulglycotide, while ebrotidine and sulglycotide were found to be most effective inhibitors of H. pylori lipolytic activities. 4. The gastric epithelial integrity is compromized by the H. pylori cell-wall lipopolysaccharide untoward effect on the epithelial surface receptors. The interference of the lipopolysaccharide with the laminin receptor was found to be most efficiently countered by ebrotidine, sulglycotide and sucralfate, whereas sulglycotide is the most potent in the reversal of the inhibitory effect of the lipopolysaccharide on mucin receptor binding.
Research Center, University of Medicine and Dentistry of New Jersey, Newark 07103-2400.
B L
BL
Slomiany
V L
VL
Murty
J
J
Piotrowski
A
A
Slomiany
D000818:Animals; D001422:Bacterial Adhesion / Q000187:drug effects; D010450:Endopeptidases / Q000502:physiology; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology*; D016480:Helicobacter pylori / Q000201:enzymology / Q000502:physiology*; D006801:Humans; D008049:Lipase / Q000502:physiology; D009077:Mucins / Q000502:physiology; D009093:Mucus / Q000378:metabolism; D012795:Sialoglycoproteins / Q000494:pharmacology; D013429:Sulfatases / Q000378:metabolism
D009077:Mucins; D012795:Sialoglycoproteins; C009354:sulglicotide; D008049:Lipase; D013429:Sulfatases; C022758:glycosulphatase; D010450:Endopeptidases